Seven manufacturers of pharmaceuticals may for the time being continue marketing their generic products based on the HIV drug Truvada in Germany. The Regional Court of Munich rejected the applications of the US pharma concern Gilead for interim injunctions against Aliud, Betapharm, Hexal, Hormosan, Mylan dura, TAD and Zentiva.
Representatives from Maiwald: Dr Dirk Bühler, Heike Röder-Hitschke, Dr Derk Vos, and Dr Annelie Wünsche
The complete JUVE article can be downloaded under: http://www.juve.de/nachrichten/verfahren/2017/09/hiv-medikament-zahlreiche-patentrechtler-flankieren-patentstreit-um-truvada
